To date, 12 placebo-controlled studies have evaluated the antidepressant
efficacy of duloxetine at dosages of 40–120 mg/day.
Many of these had an active drug comparator group. Efficacy was
measured by remission, the optimal outcome measure, or by response.
Remission can be operationally defined as a score of less than or
equal to 7 on the 17-item Hamilton Rating Scale for Depression (Ham-D)
or a score of less than or equal to 10 on the Montgomery-Åsberg
Depression Rating Scale (MADRS). Response is often defined as a
50% reduction in the MADRS or Ham-D score from baseline
to endpoint. These studies and non-placebo-controlled duloxetine
trials are summarized in Tables 23–2 and 23–3.